TABLE 1.
Characteristics of included studies. a
| Study, year | Design | Funding | Patients on fostamatinib | Country | Age, years b | Male, n (%) | Duration of ITP, years b | Prior treatments b , c | Splenectomy (%) | Baseline platelets, ×109 cells/L b |
|---|---|---|---|---|---|---|---|---|---|---|
| Kuwana, 2023 [18] | Phase III RCT | Industry | 22 | Japan | 61 (25–81) | 4 (18) | 12 (1–41) | 2 (1–7) d | 5 (23) | 19 (3–28) |
| Bussel, 2018 [16] | Two Phase III RCTs | Industry | 101 | International | 54 (20–88) | 40 (40) | 8.7 (0.3–53) | 3.0 (1–13) | 34 (34) | 16.1 (1–51) |
| FIT‐1 | 51 | North America, Europe, Australia | 57 (20–88) | 21 (41) | 7.5 (0.6–53) | 3 (1–9) | 20 (39) | 16.2 (1–51) | ||
| FIT‐2 | 50 | Europe | 50 (21–82) | 19 (38) | 8.8 (0.3–50.2) | 3 (1–13) | 14 (28) | 15.9 (1–33) | ||
| Dranitsaris, 2023 [30] | Retrospective cohort | Industry | 51 | United States | 59 (21–88) | 16 (31) | 4.5 (1–21) | 3 (2–6) | 20 (39) | 21 (4–46) |
| Bussel, 2022 [23, 36] | Retrospective cohort abstract | Industry | 318 | NR | 67 (19–100) | NR | NR | NR | NR | 32 (NR) |
| Moezi, 2022 [37] | Retrospective cohort abstract | Industry | 46 | United States | 58 (NR) | 16 (35) | NR | 2 (NR) | 16 (35) | 19 (3–70) |
| Cooper, 2021 e [20] | Prospective cohort (FIT‐3) | Industry | 146 | NR | 53 (20–88) | 58 (40) | 8.4 (<1–53) | 3 (1–13) | 51 (35) | 16 (NR) |
| Podolanczuk, 2009 [19] | Prospective cohort | Industry | 16 | United States | 66 (31–81) | 6 (38) | 9 (1–≥29) | 5 (2–≥3) | 11 (69) | 16 (2–28) |
| Grantab, 2022 [38] | Case series abstract | NR | 5 | NR | 77 (56–94) | 3 (60) | 5 (0.6–18) | 2 (2–5) | 0 (0) | 14 (<10–26) |
| Liu, 2022 [21] | Case series | None | 7 | United Kingdom | 80 (63–94) | 3 (43) | 6 (0.5–30) | 2 (1–6) | 1 (14) | 25 (10–193) |
| Mehta, 2022 [22] | Case series | Industry | 5 | NR | 79 (60–90) | 4 (80) | 6 (0.2–8.3) | 2 (1–6) | NR | 39 (17–59) |
| Hughes, 2021 [39] | Case series | NR | 5 | NR | 69 (22–75) | 3 (60) | 6 (1–8) | 3 (3–6) | 1 (20) | 35 (4–264) |
Abbreviations: ITP, immune thrombocytopenic purpura; RCT, randomized controlled trial.
a
NR, not reported.
b
Unless otherwise noted, values are the median (range [i.e., minimum, maximum]).
c
Prior unique treatments counted as falling within the following categories: corticosteroid, IVIG/IV Anti D, thrombopoietin (TPO) agents, immunosuppressants, splenectomy, rituximab, danazol, chemotherapy, and other (i.e., dapsone).
d
Kuwana et al. report splenectomy separately and is not included in this count.
e
Cooper et al. (FIT‐3) is a prospective cohort that includes follow‐up of participants from the FIT‐1 and FIT‐2 randomized trials.